Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will

BMS' Opdivo/Yervoy combo hits a snag in adjuvant melanoma

AstraZeneca, Merck cue up FDA verdict on selumetinib next ye...

FDA decision on Opdivo/Yervoy in liver cancer due next March

First Rituxan biosimilar Truxima set to make its debut in US

UK startup Ervaxx targets ‘dark matter’ of human genome